selective anticoagulation

PreclinicalSmall molecule

selective anticoagulation is one of 25 small molecule programs targeting Thromboembolism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThromboembolismActive, not recruiting

ThromboembolismPreclinical

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Thromboembolism

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

—2

Heparin Sodium

BBaxter Healthcare Corporation

Approved

1 3

Coumadin

Nadroparin

1 5

Xylocaine

MMEDRx USA, Inc.

Approved

—6

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lovenox

2 8

Lovenox

Sanofi

Phase 3

1 9

Urokinase

Mmedac GmbH

Approved

1 10

Unfractionated Heparin

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thromboembolism1 trial

Selective Thromboembolism Prophylaxis After Arthroplasty

Completed·GGuangdong Provincial People's Hospital·N/A·NCT03804697·197 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for selective anticoagulation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — selective anticoagulation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for selective anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangdong Provincial People's Hospital

selective anticoagulation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thromboembolism1 trial

References

Drug Info

Quick Facts

Related News